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Abstract
Seasonal Malaria Chemoprevention (SMC) is recommended for children under 5 in the Sahel and
sub-Sahel. The burden in older children may justify extending the age range, as has been done ef-
fectively in Senegal. We examine costs of door-to-door SMC delivery to children up to 10years by
community health workers (CHWs). We analysed incremental financial and economic costs at dis-
trict level and below from a health service perspective. We examined project accounts and pro-
spectively collected data from 405 CHWs, 46 health posts, and 4 district headquarters by introduc-
ing questionnaires in advance and completing them after each monthly implementation round.
Affordability was explored by comparing financial costs of SMC to relevant existing health expend-
iture levels. Costs were disaggregated by administration month and by health service level. We
used linear regression models to identify factors associated with cost variation between health
posts. The financial cost to administer SMC to 180000 children over one malaria season, reaching
93% of children with all three intended courses of SMC was $234 549 (constant 2010 USD) or
$0.50 per monthly course administered. Excluding research–participation incentives, the financial
cost was $0.32 per resident (all ages) in the catchment area, which is 1.2% of Senegal’s general
government expenditure on health per capita. Economic costs were 18.7% higher than financial
costs at $278 922 or $0.59 per course administered and varied widely between health posts, from
$0.38 to $2.74 per course administered. Substantial economies of scale across health posts were
found, with the smallest health posts incurring highest average costs per monthly course adminis-
tered. SMC for children up to 10 is likely to be affordable, particularly where it averts substantial
curative care costs. Estimates of likely costs and cost-effectiveness of SMC in other contexts must
account for variation in average costs across delivery months and health posts.
Keywords: Seasonal malaria chemoprevention (SMC), intermittent preventive treatment, malaria, cost function, cost variation,
primary health care, community health workers, mass drug administration, campaigns, Sub-Saharan Africa
VC The Author 2017. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. 1256
Health Policy and Planning, 32, 2017, 1256–1266
doi: 10.1093/heapol/czx084
Advance Access Publication Date: 24 July 2017
Original Article
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/h
e
a
p
o
l/a
rtic
le
-a
b
s
tra
c
t/3
2
/9
/1
2
5
6
/4
0
3
0
7
4
3
 b
y
 L
o
n
d
o
n
 S
c
h
o
o
l o
f E
c
o
n
o
m
ic
s
 u
s
e
r o
n
 2
8
 N
o
v
e
m
b
e
r 2
0
1
9
Introduction
In 2012, the World Health Organization (WHO) recommended
Seasonal Malaria Chemoprevention (SMC) for children under 5 liv-
ing in areas of the Sahel and sub-Sahel with highly seasonal malaria
transmission (World Health Organization 2012). Previously known
as intermittent preventive treatment of malaria in children (IPTc),
SMC consists of providing a treatment dose of an effective antimal-
arial on a monthly basis for three or four consecutive months of the
year in order to maintain therapeutic levels of antimalarial drugs
during the period of greatest malaria risk. SMC with sulfadoxine
pyrimethamine (SP) plus amodiaquine (AQ) is a highly efficacious
intervention, which clinical trials showed to reduce the incidence of
malaria by 75% or more amongst children under five who received
it in areas of highly seasonal transmission (Bojang et al. 2011; Dicko
et al. 2011; Konate et al. 2011; Sinclair et al. 2011; Wilson 2011).
A large-scale, stepped-wedge, cluster-randomized trial in Senegal
found that delivering SMC to children under 10 reduced malaria in-
cidence by 60% (95% CI 54–64) amongst children under 10 and by
26% (95% CI 18–33) in adults and children older than 10 who did
not receive SMC, through indirect effects (Cisse et al. 2016).
Preliminary findings regarding feasibility, safety, effectiveness and
costs from this large-scale study were requested and reviewed by
WHO’s Technical Expert Group on Preventive Chemotherapy in
2011 (World Health Organization/Global Malaria Program
Technical Expert Group on Preventive Chemotherapy 2011), which
subsequently recommended SMC.
Since the WHO recommendation, 12 countries have begun de-
livering SMC and 7 of these countries have been supported by a
$67 m grant from UNITAID to expand access to SMC (Malaria
Consortium 2016). While 11 of these countries provide SMC for
children up to 5 years of age in accordance with the WHO recom-
mendation, on the basis of the large-scale study findings, Senegal’s
policy since 2013 has been to provide SMC to children up to age 10.
Policy makers and programme managers in other Sahel countries are
considering whether to extend the recommended age range for SMC
to address the increasing proportion of the malaria burden falling on
older children.
As SMC requires repeated contacts with the health system out-
side the existing schedule of vaccinations and health campaigns, the
feasibility and cost of reaching children in rural areas on a large
scale have been important factors in deliberations on SMC (World
Health Organization/Global Malaria Program Technical Expert
Group on Preventive Chemotherapy 2011). Studies which examined
potential delivery strategies concluded that community health work-
ers (CHWs) need to play an important role in implementation
(Kweku et al. 2009; Bojang et al. 2011; Patouillard et al. 2011).
Economic evaluations were conducted alongside several SMC
studies to explore which drug combinations and delivery strategies
were most cost-effective (Conteh et al. 2010; Bojang et al. 2011;
Patouillard et al. 2011), but these were relatively small-scale trials,
which may overestimate both the costs and feasibility of implement-
ing SMC at scale. Nonvignon et al. (2016) also examined the cost-
effectiveness of SMC implementation with intensified household vis-
its. As all economic evaluations published to date have been con-
ducted amongst younger children, however, they do not directly
address questions about whether to extend the recommended age
range.
We provide an economic analysis of the costs of administering
three monthly courses of SMC in 2010 to a population of over
180000 children aged 3months to 10 years in central Senegal in the
context of the step-wedge trial previously described (Cisse et al.
2016). >93% of children in the target age range received all three
intended monthly courses of treatment (Ba et al. 2017); delivery was
highly equitable (Ba et al. 2017) and safe (N’Diaye et al. 2016) and
reduced the prevalence of molecular markers of resistance to SMC
drugs (Cisse et al. 2016). Extending the preliminary findings re-
viewed by WHO, we provide a comprehensive analysis of cost driv-
ers, the distribution of costs across the 3months of administration
and across health system levels, variation in costs between health
posts, and economies of scale. We aim to inform decisions on
whether to extend the recommended age range for SMC and draw
conclusions of wider relevance to the implementation of other large-
scale health campaigns and the organization of the health system.
Methods
Study setting and design
Details of the step-wedge study design (Cisse et al. 2016) and study
setting (Ba et al. 2017) are provided elsewhere. In brief, following
two seasons of piloting in a neighbouring district, 54 rural and semi-
urban public health post catchment areas in 4 districts (Bambey,
Mbour, Fatick and Niakhar) were randomized to start implement-
ing SMC in 2008 (9 catchment areas), 2009 (18 catchment areas) or
2010 (18 catchment areas). Cost data were collected in 2010, when
45 catchment areas (comprising 45 public health posts and 1 mis-
sion facility) implemented SMC.
Senegal was classified as a low-income country until 2011, and
was reclassified as such in 2017 (World Bank 2017). In the imple-
mentation area, 32% of the population was under 10 years old
(Cisse et al. 2016). The area’s rainy season runs from July to early
October and the climate is sudano-sahelian, leading to highly sea-
sonal transmission. While the malaria burden had been very high, it
had fallen by 2010, when malaria incidence in the study’s control
areas (confirmed by a rapid diagnostic test, RDT) was 4.3 cases per
Key Messages
• Our estimates of the costs of SMC are lower than previous studies, which may be attributed to the wider age range
(0–10 vs 0–5years), much larger overall scale of delivery, and more limited involvement of researchers in implementa-
tion in our study.
• We observed substantial economies of scale in the size of the catchment area of health posts; the average cost curve
was L-shaped, consistent with the limited existing empirical literature on provider costs.
• The financial costs of providing SMC for children under ten represent 12% of combined government and international
spending on malaria in Senegal and 1.2% of Senegal’s general government expenditure on health per capita, making
SMC potentially affordable especially if it were to avert substantial curative care costs.
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thousand children under 5 and 10.0 cases per thousand children
aged 5–10 (Cisse et al. 2016). In 2014, malaria continued to account
for 5.0% of deaths in children under 5 and 3.4% of all deaths in
Senegal (PNLP 2015).
SMC delivery strategy
The existing CHW network, which already delivered a variety of
interventions including twice yearly Vitamin A and anthelminthic
tablets for children under 5 through door-to-door strategies, was
identified as most appropriate for SMC distribution. Under the
supervision of the head nurse at each health post, CHWs travelled
door-to-door on designated days in September, October, and
November to administer the first dose of loose, crushable AQ and
SP tablets each month to children aged 3–119months and to provide
AQ tablets for the child’s caregiver to administer using the house-
hold’s usual water supply on the subsequent 2 days. In 2010, imple-
mentation was organized primarily by the district health
management teams (DHMTs).
The head nurse at each health post trained CHWs over the
course of several hours on the day before administration in
September, but did not repeat this full training in October and
November. For CHWs who missed this initial training, informal,
on-the-job training was provided, as is standard practice for cam-
paigns. Each head nurse was responsible for organizing the hiring of
CHWs and deciding the number of days they were hired for and
their payment. Health posts received a lump sum to cover CHW in-
centive payments, based on the estimated number of CHWs needed
and the estimated number of days work it would take the CHWs to
cover the target population of the health post. Some nurses chose to
divide the lump sum by the number of CHWs associated with their
health post and pay CHWs a fixed amount, while others paid a daily
rate (Ba et al. 2017).
Perspective and hierarchical boundaries
Detailed data on resource use associated with delivery of SMC were
collected to estimate the incremental costs of implementing SMC at
scale in 2010. All 45 government health posts that delivered SMC in
2010 were included, as was one mission health post which managed
SMC delivery within a defined portion of the official catchment area
of one of the 45 government health posts.
The study takes a health service perspective. The opportunity
cost for households to participate in SMC is expected to be low as
SMC is delivered door-to-door (Conteh et al. 2010).
Both financial and economic costs are included. Incremental fi-
nancial costs reflect the additional funding needed to pay for the
intervention. Incremental economic costs reflect the full value of the
additional resources used to implement SMC, including those which
did not incur an incremental financial cost to the health service,
such as the time required of the district health team and health post
staff, and items paid for by CHWs or other organizations. The
economic value of individuals’ time was calculated as a fraction of
their salaries (including benefits) or, for CHWs, estimated earnings,
assuming 220 working days per year and an average 7.5-h
working day.
We focus on costs of implementation at the district level and
below. Costs incurred only at national level, such as those associated
with meetings amongst national-level representatives, are not
included because they only concerned research; implementation
questions were devolved to district managers. Nearly all the costs of
implementation from the district level and below were considered
recurrent, meaning that they would have to be repeated for each
year of implementation. The only capital costs (resources that last
over a year) associated with SMC implementation were those of the
research team vehicles, which were used in a few instances to sup-
port the distribution of SMC drugs and supervision. Straight line de-
preciation of the purchase price of vehicles was used with a 5-year
expected life of the vehicle (based on local usage) and an assumption
of 220 working days per year to estimate the daily economic value
of these vehicles, in addition to the financial costs of fuel.
Costs of research activities were generally excluded from the
analysis. In two cases, however, costs associated with research activ-
ities were very likely to have contributed directly to the success of
the administration and so they have been included and described in
detail. First, all costs of the demographic surveillance system (DSS)
set up to support the trial were excluded, however, some of the DSS
fieldworkers and supervisors provided supervisory support on the
administration days in September and October and transported
some of the drugs; the costs of their time and of drivers and vehicles
for these implementation activities have, therefore, been included
under supervision and supply chain, respectively. As it is standard
practice for districts and health posts to request the support of local
organizations such as NGOs or research institutes for health cam-
paigns, these costs are considered incremental economic costs, but
not incremental financial costs to the Ministry of Health. Second,
health staff at post, district, and regional levels received incentives
for participation in the research. These incentives were paid over
12months and were intended to support participation in research
activities such as morbidity surveillance. While it is not anticipated
that such incentives would be paid if SMC were implemented out-
side a research context, these incentives may have contributed to
more assiduous implementation of SMC, and so they are also pre-
sented as a separate cost category.
Data collection
Tools were developed to collect data on costs and resource use at
four levels: the project, the district, the health post, and the CHW.
At the district, health post, and CHW levels, questionnaires were de-
veloped, introduced to all district medical officers, head nurses, and
CHWs at the SMC planning meetings before administration began
in 2010, and refined to incorporate their feedback. Trained field-
workers collected data from all 4 districts and all 46 health posts fol-
lowing each round of administration in September, October, and
November. They also administered questionnaires to a systematic
sample of CHWs each month. In total, 405 CHW interviews were
conducted, reflecting 48% of the average of 822 CHWs who admin-
istered SMC each month, or 13% of the CHW-months of adminis-
tration. District and health post questionnaires and health post and
CHW questionnaires covered similar questions regarding resource
use, activities, and payments so that data could be triangulated. In
addition, several key informant interviews were conducted with
local field coordinators and CHWs to compare the per diems paid to
CHWs with what they could otherwise have earned on the SMC ad-
ministration days.
In November, three health posts in Bambey District combined
administration of SMC with administration of Vitamin A and
mebendazole. For these three posts, and in some cases for Bambey’s
district-level costs, the cost of delivering SMC alone in November
was estimated based on the costs incurred in these health posts in
October.
1258 Health Policy and Planning, 2017, Vol. 32, No. 9
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Data management and analysis
Questionnaire data were entered into an MS Access database.
Consistency checks were performed to ensure data validity and data
were exported to MS Excel for analysis. Data were carefully triangu-
lated between sources to maximize accuracy and avoid double-
counting. Costs are presented in United States Dollars (USD) based
on the average 2010 exchange rate with the West African Franc
(1 USD¼495 XOF(OANDA)).
Costs were summarized according to the categories presented in
Table 1. These categories were identified to ensure comparability
with previous studies of SMC (Conteh et al. 2010; Bojang et al.
2011) and to reflect the key cost centres. We present key cost drivers
and examine several aspects of the cost structure and cost variation.
To facilitate projections of how costs may vary if fewer or more
monthly rounds of SMC were implemented, we disaggregated costs
by the month in which they were incurred. To facilitate projections
of how costs may vary with different scales of delivery and in differ-
ent areas, we disaggregated costs by the health system level (district,
health post, CHW, child) with which they would be expected to
vary approximately linearly.
Costs are analysed with respect to several measures of output
described in detail elsewhere (Ba et al. 2017) (Table 2). Estimates of
the number of monthly courses administered were based on admin-
istrative data, which was triangulated from routine data in health
post reports and administration registers. Estimates of the number
of children in the target age range and all residents in the catchment
area were based on the DSS. The number of children receiving SMC
at least once and in all 3months was estimated by applying survey
Table 1. Description of cost categories
Cost category Description
SMC drugs Reflects the cost of SP and AQ tablets supplied by National Pharmacy of Senegal and Kinapharma (Accra, Ghana),
respectively and actually used or wasted during SMC administration, including the costs of importation to the
Port of Dakar
Drug transport/supply chain Reflects the cost of transporting drugs from Dakar to the districts (via a local storage site) by the research team, and
from the districts to the health posts by district and health post staff. Additional economic costs include the value
of time and of vehicles used by the research team, districts, and health posts
Drug administration (CHWs) Includes the cost of payments of per diems to and transport for CHWs to come to the health post, retrieve drugs
and registers, administer drugs to children, and return to the health post to return their reports and remaining
drugs on each day of the administration. Additional economic costs include transport costs paid by the CHW
and not reimbursed by the health facility
Supervision Reflects the cost of incentive payments to a head nurse, assistant, and in some cases trainee at each health post; to
each district health management team, region, and prefecture to supervise the implementation of SMC and to
manage any side effects or refusals; and the costs of any transport used for this supervision. Additional economic
costs include the value of time and transport for these health staff as well as the DSS supervisors and fieldworkers
for the days on which they helped districts to supervise the administration
Training of CHWs CHWs attended a single training day at their health post before administration in September. The payment of per
diems, as well as the costs of any food or supplies provided or used during the training and any transport paid for
by the health post or district are included as financial costs. Additional economic costs include the value of health
staff time
Training of head nurses Head nurses travelled to their district headquarters for a one-day training before administration in September.
Costs were incurred for the per diems paid to the head nurses, their transport, and the food and supplies pro-
vided. Additional economic costs include the value of participants’ time and of vehicles used
Meetings (evaluation & planning) Prior to the training, head nurses attended one or more evaluation and planning meetings at their district during
which they evaluated results of the SMC implementation in 2009 and outlined plans and budgets for implementa-
tion of SMC in 2010. Costs include per diems, transport, and any food or materials provided specifically for the
meetings. Meetings were held for head nurses at district level and for district managers in Dakar and at one of the
districts
Sensitization Both districts and health posts arranged activities such as travelling caravans, radio announcements, and commu-
nity meetings to promote awareness of SMC with regional or local authorities and within the community.
Additional economic costs include the value of participants’ time and vehicle use
Drugs for side effects The costs of the small stock of drugs and medical supplies with which to manage potential adverse events provided
to health posts were included regardless of the amount used, as these supplies would need to be provided in future
as a precaution. In addition, head posts were reimbursed the cost of treating children whose parents reported side
effects, in cases where the head nurse used medications other than those provided
Supplies Supplies used in the administration included hats, t-shirts, and polo shirts with SMC sensitization messages and the
MoH logo; registers of children and other monitoring tools; phone cards, etc. In addition, health posts also pur-
chased some supplies themselves, such as pencils and erasers, to complement those provided by the district.
Supplies purchased by CHWs are included as economic, rather than financial costs to the health service
Research participation incentives Regional medical officers, district medical officers and their deputies, district supervisors, and head nurses all
received quarterly incentive payments throughout the year to support research activities such as morbidity sur-
veillance. The entire value of these payments over 12months to the 3 regions, 4 districts, and 45 health posts that
implemented SMC in 2010 are included, as they are likely to have contributed to more assiduous implementation
of SMC in September, October, and November. It is not expected that this level of incentive payment would be
repeated outside a research context
This table provides a detailed description of the cost categories used in the analysis. Where economic costs are greater than financial costs, the source of add-
itional economic costs are mentioned explicitly.
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estimates of the proportion of children receiving 0, 1, 2, or 3 courses
of SMC to the administrative estimate of the number of monthly
courses administered. The latter was a conservative approach yield-
ing lower estimates of the number of children receiving SMC (and
thus higher costs per course and per child) than applying survey esti-
mates to the target population estimated in the DSS.
Affordability was explored by assessing the annual financial cost
of SMC per person (all ages) resident in the catchment area as a pro-
portion of three relevant, existing expenditure levels. These were:
(1) average annual expenditure for malaria control and elimination
per person at risk in Senegal (which includes both domestic expend-
iture on malaria prevention and treatment and donor funding ear-
marked for malaria control) in 2013–2015 (WHO Global Malaria
Programme, 2016); (2) Senegal’s general government expenditure
on health per capita in 2014 (World Health Organization 2017) and
(3) Senegal’s total health expenditure per capita in 2014 (World
Health Organization 2017). The most recent expenditure levels
available are used to explore affordability relative to current fund-
ing, but are presented in constant 2010 USD to allow comparison
with our cost estimates.
We sought to identify factors associated with variation between
health posts in the average cost of SMC administration per course
administered. We analysed average economic costs including re-
search participation incentives with the district-level costs divided
equally among the health posts within each district. We hypothe-
sized that the following observed variables could be associated with
cost variation across health posts: the number of courses adminis-
tered (i.e. output or scale), coverage, geography of the catchment
area (minimum, average, and maximum distances from health post
to catchment villages; catchment area; number of catchment vil-
lages), and the number of years of experience (of the head nurse
and, separately, at the health post) of delivering SMC (0, 1, or 2).
Coverage estimates (the number of courses administered as a pro-
portion of the target) were based on administrative, rather than sur-
vey data, because survey-based coverage estimates were not
available for each health post (Ba et al. 2017). As our observations
(health posts) were nested within a small number of clusters (dis-
tricts), we fit a linear model with fixed effects at the district level
(Mo¨hring 2012) to account for this clustering. We used STATA 14.
All independent variables were centred. Scatter plots of all pairwise
variable combinations were used to assess the linearity of relation-
ships; logarithmic transformations were performed on skewed data
and a quadratic term was added for any independent variables ex-
hibiting a curvilinear relationship with costs. Possible interactions
between the number of courses administered, coverage, and catch-
ment area were explored. We began with a full model containing all
independent variables and interaction terms and sequentially
removed the variable from the model with the highest P-value.
Variables were retained in the model if they contributed to the fit of
the model with P<0.05, if removal substantially altered coefficients
of other variables in the model, or if they were component variables
of retained interaction or quadratic terms. Once a parsimonious
model was reached, excluded variables were individually retested.
Standard regression diagnostics were performed (Chen et al. 2003).
Likelihood ratio tests were used to determine whether individual
variables and groups of variables improved model fit. We also de-
veloped a more parsimonious model based on a more stringent cri-
terion of P<0.0032, which corresponds with a Bayes factor of 20
(Altman and Krzywinski 2017) (Supplementary Materials are avail-
able atHEAPOL online).
Results
Costs and affordability
The financial cost to administer SMC to a population of over
180000 children aged 3months to 10 years in four districts of
Senegal over one malaria season, reaching an estimated 93% (95%
CI 91–96) of children with all three monthly courses of SMC (Ba
et al. 2017) was $234549 (Table 3) or $0.50 per monthly course ad-
ministered (Table 2). The economic costs were 19% higher at
$278922 or $0.59 per course administered. When the value of in-
centives intended for research is removed, the financial and eco-
nomic costs fall by $43 424 to $0.41 and $0.50 per course
administered, respectively. This financial cost of $0.41 per course
administered excluding research participation incentives corres-
ponds to $1.22 per child receiving all three scheduled courses, $1.06
per child of target age in the catchment area, and $0.32 per resident
(all ages) in the catchment area (Table 2).
This cost per resident represented 1.2% of Senegal’s general gov-
ernment expenditure on health per capita, 0.6% of total health ex-
penditure per capita and 12% of combined government and
international spending on malaria in Senegal (Supplementary Table
S1 is available at HEAPOL online).
Table 2. Financial and economic cost of SMC per output
Denominator Number Cost of SMC per output (US$)
Financial Economic
Excluding research
incentives
Including research
incentives
Excluding research
incentives
Including research
incentives
Monthly courses administereda 471,283 $0.41 $0.50 $0.50 $0.59
Children receiving SMC at least onceb 157,654 $1.21 $1.49 $1.49 $1.77
Children receiving SMC in all three monthsb
(i.e. "fully adherent")
156,311 $1.22 $1.50 $1.51 $1.78
Children of target age in the catchment areac 181,060 $1.06 $1.30 $1.30 $1.54
Residents (all ages) of the catchment areac 589,332 $0.32 $0.40 $0.40 $0.47
aBased on administrative data, which was triangulated from routine data in health post reports and administration registers (Ba et al. 2017).
bGenerated by applying survey estimates of the proportion of children receiving 0, 1, 2, or 3 courses of SMC to the estimate of the number of monthly courses
administered based on administrative data (Ba et al. 2017).
cBased on the DSS (Ba et al. 2017).
1260 Health Policy and Planning, 2017, Vol. 32, No. 9
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Cost drivers
The main cost drivers were door-to-door drug administration (42%
of non-research financial costs) and SMC drugs (28% of non-
research financial costs, Table 3). Per diems paid to CHWs ac-
counted for most of the drug administration costs and 41% of total
non-research financial costs (Supplementary Table S2 is available at
HEAPOL online). AQ tablets alone accounted for 21% of non-
research financial costs, while SP tablets accounted for 7%.
Incentives paid to nurses and district staff for participation in the re-
search study increased the financial costs of the intervention by 23%
(from $191049 to $234462). While research incentives were in-
tended to support data collection rather than implementation and
are not normally provided for comparable distribution campaigns,
they may have contributed to the high coverage levels achieved, as
on average they represented a 7% increase in head nurses’ annual
salaries—or 15 days’ pay assuming 220 days worked per year—
and a>10% increase in the salaries of district and regional staff
(Supplementary Table S1 is available at HEAPOL online). Publicity
campaigns and other sensitization activities played an important
role in achieving high coverage (Ba et al. 2017), although they ac-
counted for only 1% of financial and economic costs.
Economic costs were $43945 greater than financial costs be-
cause they also included the value of the time MoH staff and others
spent in meetings, trainings, travel and supervision (74% of the add-
itional costs), as well as the economic value of vehicles used and the
cost of supplies paid for by CHWs while implementing the interven-
tion. Key informant interviews revealed that the payments made to
CHWs (median: $7.49 per day, range $5.05–16.16) were compar-
able to or greater than the daily rate of pay for agricultural labour,
similar to rates paid by non-governmental organizations (NGOs) for
health activities, and somewhat higher than health districts pay for
other mass campaigns. While the qualifications and opportunities
amongst CHWs varied, many were illiterate and unskilled and
others were secondary school students (Ba et al. 2017). In addition,
distribution tended to begin on weekends to ensure both that fami-
lies were at home and that CHWs would be available without taking
them away from other activities (Ba et al. 2017). The economic
value of CHW time spent implementing the intervention was there-
fore considered to be fully reflected in the financial costs of the pay-
ments made to them, and so no additional economic costs of CHW
time were calculated.
Time allocation
Most CHWs worked in pairs, delivering SMC to a mean of 46 chil-
dren per CHW per day at each health post (range 25–78)
(Supplementary Table S3 is available at HEAPOL online). Some
Table 3. Total financial and economic costs of SMC
Financial costs Economic costs
Total costs
US$ (2010)
Cost profile Total Costs
US$(2010)
Cost profile
Including research
incentives (%)
Excluding research
incentives (%)
Including research
incentives (%)
Excluding research
incentives (%)
TOTAL including research incentives $234 549 100.0 NA $278 922 100.0 NA
TOTAL excluding research incentives $191 125 NA 100.0 $235 498 NA 100.0
SMC drugs (SPþAQ) $53 010 22.6 27.7 $53 010 19.0 22.5
Drug transport/supply chain $425 0.2 0.2 $3266 1.2 1.4
Drug administration (CHWs) $80 651 34.4 42.2 $80 651 28.9 34.2
Supervision $25 156 10.7 13.2 $57 563 20.6 24.4
Training of CHWs $6946 3.0 3.6 $8956 3.2 3.8
Training of head nurses $2283 1.0 1.2 $3813 1.4 1.6
Meetings (evaluation & planning) $2365 1.0 1.2 $3851 1.4 1.6
Sensitization $2519 1.1 1.3 $2962 1.1 1.3
Drugs for side effects $2491 1.1 1.3 $2491 0.9 1.1
Supplies $15 279 6.5 8.0 $18 935 6.8 8.0
Research participation incentives $43 424 18.5 NA $43424 15.6 NA
Table 4. Cost of activities by health system level and month of administration
Level Financial costs Economic costs
Sept (and earlier) Oct Nov Total costs Cost profile (%) Sept (and earlier) Oct Nov Total costs Cost profile (%)
District $7019 $4234 $5549 $16 801 8.8 $12 235 $7028 $7010 $26 274 11.2
Post $22 456 $7311 $8809 $38 576 20.2 $37 521 $14 987 $15 416 $67 924 29.1
CHW $6920 $16 $9 $6946 3.6 $6920 $16 $9 $6946 3.0
Child $43 939 $42 506 $42 356 $128 802 67.4 $45 351 $43 632 $43 475 $132 457 56.7
Total $80 334 $54 067 $56 723 $191 125 100.0 $102 027 $65 664 $65 910 $233 601 100.0
Cost profile (%) 42.0 28.3 29.7 100.0 43.7 28.1 28.2 100.0
Costs are attributed to the lowest level with which they would be expected to increase linearly. For example, if the number of CHW were doubled, but all else
held constant, the CHW-level costs would be expected to double while other levels would remain approximately constant. Similarly, adding an additional month
to the campaign would add 28–30% to total costs, assuming that this additional month’s campaign was conducted similarly to the October and November cam-
paigns, rather than the September campaign, which incurred additional start-up costs, especially for meetings and trainings. Research participation incentives are
excluded.
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CHWs assisted with administrative duties in the health post for
some or all of the administration days and so administered few or
no courses directly; hence, for individual CHWs who administered
at least one course, the average number of courses administered per
day varied more widely, from 2 to 169. Health posts employed from
4 to 68 CHWs and delivery each month took from 2 to 6 days per
post. CHWs worked a mean of 7 h per day, but this varied from 1 to
12 h across CHWs and the average number of hours per day per
CHW also varied substantially between health posts, from an aver-
age of just 4 h per day in one health post to an average of 10 h per
day in another (Supplementary Table S3 is available at HEAPOL
online). CHW time spent on SMC was only moderately (22%)
higher in September (mean 665 cumulative CHW-hours per health
post) than in each subsequent month (543h) (Supplementary Table
S4 is available at HEAPOL online). Head nurses spent a median of
75 cumulative hours on SMC over the 3months (range 7–156),
more than two-thirds of which was spent on the September round
(Supplementary Table S4 is available at HEAPOL online).
Across the four districts, district medical officers spent a median
78h (range 12–116) on SMC, while their deputies spent substantially
less time (Supplementary Table S4 is available at HEAPOL online).
District supervisors spent a median 209h per district (range 42–376)
on SMC. Supervisors and fieldworkers from the DSS supported
supervision in September and October, spending the largest amount
of time in the district whose supervisors and senior officers spent the
least time on SMC. The additional time district and health post staff
spent in September relative to the two subsequent months was largely
spent in meetings and trainings at both the district and health post
level. Several separate meetings/trainings on SMC were held at the dis-
tricts involving head nurses in August and September; discussions of
SMC did not appear to be combined in other district meetings.
Cost structure
The first of the three monthly SMC rounds accounted for 42% of fi-
nancial costs (Table 4). Adding a fourth monthly SMC round would
be expected to increase total costs by 28–30%, assuming that the
additional month’s campaign were conducted similarly to the
October and November campaigns.
Two-thirds of financial costs (67%) were expected to vary with
the number of children, while 20% were expected to vary with the
number of health posts (Table 5). Only 9% of financial costs were
expected to vary with the number of districts, while <4% of costs
were expected to vary with the number of CHWs. Thus, for ex-
ample, if a new health post were created to serve half the catchment
population of the largest health post in our study, we could assume
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Figure 1. Total and average costs by health post with cost drivers. Health posts are ordered (left to right) in both graphs from largest to smallest total economic
costs, including research participation incentives. District-level costs have been divided evenly across the health posts within each district. As total costs
decrease, the average cost per course administered tends to increase, although there is some variation in this trend.
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that the number of districts, CHWs and children in our analysis
would remain constant, but the number of health posts (and thus
the costs expected to vary with the number of health posts) would
increase by 2% (1/46). Holding all else constant, the addition of this
new health post could then be projected to increase the total finan-
cial costs of SMC implementation by 0.4%.
Cost variation and economies of scale across health
posts
The total economic cost varied substantially across the 46 health
posts, from $3223 to $15946 when district-level costs were appor-
tioned equally across health posts within each district and research
participation incentives were included (Figures 1 and 2). Costs
incurred only at the health post level and below varied from $1558
to $14 573. The average economic cost varied from $0.32 to $2.10
per course administered and from $0.30 to $1.38 when considering
only costs incurred at the health post level and below
(Supplementary Table S5 is available at HEAPOL online). The cost
of SMC tablets and the cost of per diems for CHWs were relatively
constant with respect to the number of courses administered (Figure
1). In contrast, the remaining significant cost centres, notably super-
vision, the additional economic value of health worker time, and the
research participation incentives, were relatively fixed with respect
to the number of health posts and thus account for most of the vari-
ation in average cost per course between health posts.
Average costs displayed a strong L-shape when plotted against the
number of courses administered (Figure 3). In this sample, there was
no evidence of a point at which health posts had such high levels of
output that they displayed diseconomies of scale. Average costs
increased steeply for health posts administering fewer than 8000
courses of SMC (10000 residents), while above 10000 courses
(12500 residents), average costs declined, but more gradually
(Figure 3). In exploring factors associated with this variation, we
found that using the more stringent, Bayesian criterion of P<0.0032
led to a parsimonious log–log model of average economic costs as a
quadratic function of the number of courses administered (including
fixed effects at the district level); this model described nearly all the
variation in the data (adjusted R2¼0.94). The more traditional, fre-
quentist threshold of P<0.05 led to a more complex model (adjusted
R2 ¼ 0.95), which also included variables for the interaction between
coverage and size of catchment area and between size of catchment
area and the logarithm of the number of courses, as well as the cover-
age and size of catchment area levels. While the likelihood ratio test
indicated that this set of additional variables improved model fit
(P¼0.020), the large number of variables relative to data points sug-
gests that the more complex model may be overspecified.
(Supplementary Table S6 are available atHEAPOL online)
Discussion
From an economic perspective, delivering SMC to children up to
10 years of age appears both affordable and sustainable, even within
the highly constrained budgets of West African health systems and
before accounting for savings from reductions in malaria cases. A
cost-effectiveness analysis would provide further information on the
Figure 2. Total economic cost vs the number of courses administered at each
health post. The figure illustrates the variation in the total costs incurred for
SMC administration between health posts. Costs incurred at the district level
are allocated equally across health posts in that district. Research participa-
tion incentives paid directly to head nurses and district health staff for trial
participation are included as they are likely to have led to more assiduous
implementation. The 46 health posts are presented with a different marker for
each of the 4 districts. Dashed line: mean total economic cost per health post
Figure 3. Economies of scale: average economic cost per course adminis-
tered vs the number of courses administered at each health post. The figure
illustrates the variation in the average economic cost per course of SMC
administered between health posts. The upper figure presents data on a
standard arithmetic scale and the lower figure illustrates the same data with
both the x-axis and y-axis presented on a logarithmic scale. Costs incurred at
the district level are allocated equally across health posts in that district.
Research participation incentives paid directly to head nurses and district
health staff for trial participation are included as they are likely to have led to
more assiduous implementation. The 46 health posts are presented with a
different marker for each of the 4 districts. Dashed line: mean economic cost
per course administered across the entire implementation area.
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value-for-money of extending the recommended age range for SMC
from children under 5 to children under 10 and on decisions regard-
ing where to implement SMC. Two analyses of the cost-effectiveness
of SMC in children under 5 have been based on findings from small-
scale trials: one trial-based analysis used “cost per case averted” as
its outcome metric (Conteh et al. 2010), making its findings difficult
to compare across health conditions, while a later analysis employ-
ing a dynamic transmission model concluded that SMC in children
under 5 is likely to be cost-effective or highly cost-effective relative
to the arbitrary, but fairly conservative thresholds of $150 and $25
(1993 USD) per disability-adjusted life-year averted (Ross et al.
2011). A third analysis estimated the cost per case averted of SMC
for children under 5 for a strategy requiring CHWs to visit each
household on five consecutive days in each of four consecutive
months (Nonvignon 2016). The cost-effectiveness of SMC in chil-
dren under 10 is likely to be highly dependent on the coverage
achieved and the age-specific incidence of malaria, both of which
can be expected to vary significantly between countries, between re-
gions within a country, and over time. We have shown that costs
also vary substantially across health posts and across distribution
rounds; this variation must also be considered in estimating the
likely costs and cost-effectiveness of SMC in other settings. In disag-
gregating SMC costs by the health system level with which they are
expected to vary, we offer a preliminary step towards taking cost
variation into account in future estimates.
Our estimates are lower than those reported in previous analyses
of SMC, which may be attributed to our study’s extended age range,
far larger target population, delivery strategy involving only one
household visit per month, and more limited involvement of re-
searchers in implementation. Previous studies of SMC examined the
costs of delivery only to children up to 5 (or in one case 6) years of
age (Conteh et al. 2010). In our study, increasing the age range for
SMC from under-5s to under-10s virtually doubled the target popu-
lation, however, it only increased the target number of households
to visit by 13%, from 80 to 90% of all households in the area, and
high coverage was maintained in both groups (Ba et al. 2017).
However, the degree to which the lower costs we observed can be
attributed to the extended age range rather than the far larger over-
all target population or other factors remains uncertain. Since our
study, co-blister packs of dispersible SPþAQ have become available,
which may increase tablet costs while potentially reducing CHW
time on administration; these and any other changes to the distribu-
tion strategy would need to be accounted for in estimates of the
likely costs of SMC in other settings.
While we have focussed on the cost per monthly course of SMC
administered as our key outcome measure, other studies of the costs
of SMC have reported the cost per “fully adherent child,” defined as
a child receiving all three (or more) intended courses of treatment.
At $1.50 excluding research incentives (Table 2), the economic cost
per fully adherent child in our study was lower than reported esti-
mates from all other studies, and even somewhat lower than projec-
tions made of the likely costs of delivering SMC at scale. Inflating
costs to 2010 USD to allow some comparison (Bureau of Labor
Statistics 2013), the lowest previously reported cost per fully adher-
ent child of a three-course SMC regimen was $1.66 using CHWs to
deliver SP and AQ in Basse, Gambia (Bojang et al. 2011; Pitt et al.
2011). A study in trial conditions in Hohoe, Volta Region, Ghana
reported the cost per fully adherent child of delivering three bi-
monthly courses of SP alone through CHWs at $8.30, but projected
a cost of $1.74 if distribution were scaled up to the district level
(Conteh et al. 2010; Pitt et al. 2011). In a wide-ranging overview of
malaria control strategies, Goodman et al. (2000) estimated the cost
of seasonal fortnightly chemoprevention with dapsone and pyri-
methamine at $1.79 (90% range $1.40–2.20) using an existing
CHW network, but requiring parents to take their children to the
health centre. Estimates were substantially higher for the four-
course strategies studied in Jasikan, Volta Region, Ghana
(Patouillard et al. 2011; Pitt et al. 2011) and in Ghana’s Upper West
Region (Nonvignon 2016), and for the three- and six-course strat-
egies employing artesunate (AS) with AQ in Hohoe (Conteh et al.
2010; Pitt et al. 2011). The “fully adherent child” metric includes
the full cost of all the doses of SMC which were administered, but
not the benefits derived by children who were protected from mal-
aria with fewer than the intended number of courses of SMC. Given
the highly mobile nature of populations both in the study area and
in other areas where SMC is likely to be of benefit, children may
have missed doses because they were away from the area and there-
fore either not exposed to malaria or potentially able to receive
SMC elsewhere if it were more widely available (Ba et al. 2017).
Although the transferability of costs across contexts depends on
many factors (Vassall et al. 2016), our financial cost estimate of
$1.22 per fully adherent child ($1.50 including research participa-
tion incentives) is within the range of costs associated with deliver-
ing other malaria prevention interventions. A systematic review
reported a median financial cost per year of protection with ITNs at
$2.20 (range $0.88–9.54, constant 2009 USD), with IRS at $6.70
(range $2.22–12.85), with IPT in infants at $0.60 (range $0.48–
1.08), and with IPT in pregnant women at $2.06 (range $0.47–3.36)
(White et al. 2011). The financial cost of school-based IPT has
been reported at $1.20 (constant 2006 USD) per child per year
(Temperley et al. 2008) and school-based intermittent screening and
treatment has been reported to cost $6.61 per child per year (con-
stant 2010 USD) (Drake et al. 2011).
Our findings of substantial economies of scale represent an im-
portant contribution to a very limited evidence base on cost vari-
ation in health service delivery in low- and middle-income countries,
particularly at the primary health care and community level and out-
side the HIV field (Brooker et al. 2008; Fiedler et al. 2014; Siapka
et al. 2014). Consistent with previous studies of HIV prevention in
India (Guinness et al. 2007; Le´pine et al. 2015; Le´pine et al. 2016)
and of school-based albendazole distribution in Uganda (Brooker
et al. 2008), we found that average costs exhibited an L-shape, and
found no evidence in our sample of a point at which average costs
would begin to increase, generating the U-shape predicted in eco-
nomic theory. While our statistical analysis remains descriptive and
was limited by the small number of data points and possibly by the
trial context and other factors, the 46 health facilities we analysed
constitute a relatively large dataset in the context of health facility
costings. Our findings may be particularly relevant for other CHW
mass distribution campaigns, such as deworming tablets and vitamin
A, and for integrated community case management programmes, for
example. They also have wider implications for the organization of
the health system; many factors, such as accessibility, must be con-
sidered in deciding on the location and catchment size of health
facilities, however, our findings demonstrate the substantially higher
costs per person reached incurred by health posts with very small
catchment areas.
Although appropriate to our study, the incremental nature of
our analysis means that the existence of a functioning health system,
including a network of CHWs, is assumed. In contexts where, for
example, head nurses cannot easily call upon a group of CHWs for
distribution campaigns, where the head nurses themselves are ab-
sent, or where districts lack the capacity to coordinate training and
distribution of incentives, medicines, and materials, additional
1264 Health Policy and Planning, 2017, Vol. 32, No. 9
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resources would need to be invested to address or circumvent these
gaps. In this way, SMC could provide an opportunity to strengthen
health systems and especially CHW networks, but doing so would
involve greater costs than reported here.
Furthermore, we have not included the costs of pharmacovigi-
lance, ongoing programme evaluation, and national-level coordin-
ation, which are important aspects of SMC implementation and will
need to be included in programme budgets. As in all such analyses,
our data may also include errors or omissions, however, our exten-
sive triangulation and comparisons across health facilities allowed
us to correct discrepancies which might not have otherwise been de-
tected. Nonetheless, collecting data on health worker time use,
which accounted for most of the additional economic costs, is par-
ticularly challenging, and may have been subject to bias or
misreporting.
Finally, while we adhered to standard practice in calculating the
economic costs of health worker time based on their salaries, it is very
unlikely that any health worker’s salary represents their value to soci-
ety, especially where they are so exceedingly scarce. Valuable health
worker time should be used as efficiently as possible, taking into ac-
count the negative effects of nurses frequently absenting themselves
from health posts to attend meetings at district level and to supervise
CHWs in door-to-door campaigns. Strong national and district-level
leadership is therefore required to bring together national child health
and disease control teams to limit the total number of off-site training
and campaign days each year. Similarly, the availability and supply of
CHWs is not infinite. In our context, the value of incentive payments
to CHWs were higher than what many CHWs could otherwise have
earned, but that does not mean that they would necessarily continue
to be willing to implement many more additional campaigns each
year. Opportunities may exist to achieve economies of scope by com-
bining SMC with delivery of other interventions, such as mass distri-
bution of ITNs, health communication, or neglected tropical disease
programmes; however, careful consideration and discussion with all
levels of health workers will be required to ensure that additional
interventions are genuinely compatible and do not cause diseconomies
of scope by unduly increasing complexity.
Conclusion
Even in the context of a highly constrained health system, door-to-
door delivery of SMC by CHWs to children under ten is likely to be
affordable, especially if it averts substantial costs of curative care.
We identified substantial variation in the cost of delivering SMC to
children in Senegal, which contributes to a very limited evidence
base on variation in provider costs. Both cost variation and the com-
parability of local health system characteristics must be accounted
for in assessing the transferability of our findings to other settings.
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